캐리어 스크리닝 시장 규모, 점유율 및 업계 분석 보고서 : 유형별, 기술별, 최종 용도별, 병상별, 지역별 전망 및 예측(2026-2033년)

The Global Carrier Screening Market is expected to reach USD 3.9 billion by 2033, growing at a CAGR of 12.3% during (2026 - 2033).

Carrier screening market is driven by rising awareness of inherited genetic disorders, increasing demand for informed family-planning decisions, and expanding access to reproductive healthcare. Market demand is growing as healthcare providers and individuals focus on preventive care, early risk identification, enhanced accuracy, broader test coverage, faster turnaround time, and personalized reproductive counselling. Carrier screening market evolved from hereditary disorder risks in offspring, and the understanding of genetic inheritance. Next-generation sequencing, PCR, enhanced bioinformatics, and expanded panels transformed the market from single-gene testing toward wider population screening.

Key Market Trends & Insights

• By type, Expanded dominated the market in 2025 with USD 1.0 billion and is expected to reach USD 2.5 billion by 2033, growing at a CAGR of 12.0%.
• Targeted Disease is expected to grow faster by type, registering a CAGR of 12.9% during (2026 - 2033), supported by family-history-based testing, ethnicity-specific screening, and condition-focused genetic risk assessment.
• By technology, DNA Sequencing dominated the market in 2025 with USD 751.4 million and is expected to reach USD 1.8 billion by 2033, growing at a CAGR of 11.7%.
• Microarrays is expected to grow fastest by technology, registering a CAGR of 13.1% during (2026 - 2033), supported by high-throughput mutation screening, multiplex testing, and cost-effective predefined variant analysis.
• By end-use, Laboratories dominated the market in 2025 with USD 709.9 million and is expected to reach USD 1.7 billion by 2033, growing at a CAGR of 11.7%.
• Physician Offices & Clinics are expected to grow fastest by end-use, registering a CAGR of 13.2% during (2026 - 2033), supported by routine reproductive health assessments, early screening adoption, and patient counseling access.
• By medical condition, Cystic Fibrosis dominated the market in 2025 with USD 524.1 million and is expected to reach USD 1.2 billion by 2033, growing at a CAGR of 10.8%.
• Regionally, North America dominated the market in 2025 with USD 667.0 million and is projected to reach USD 1.6 billion by 2033, while LAMEA is expected to grow fastest with a CAGR of 14.7% during (2026 - 2033).

Carrier screening market is expanding as next-generation sequencing, expanded panels, digital genetic counselling, and artificial intelligence enhance carrier detection and clinical interpretation. Market adoption is accelerating across prenatal screening, preconception testing, reproductive medicine, fertility care, and direct-to-consumer genetic testing. Carrier screening market further benefits from broader integration of carrier screening into stronger demand for personalized genetic insights, routine healthcare, and the need to reduce reproductive risk through early disease identification.

Competitive landscape of the market is highly dynamic and innovation-driven, supported by clinical diagnostics companies, specialized genetic testing laboratories, precision medicine organizations, and reproductive health testing providers. Companies are competing through next-generation sequencing, comprehensive screening panels, genetic counseling support, clinical validation, laboratory accreditation, digital reporting, reimbursement coverage, and AI-assisted variant interpretation. Market competition largely relies on automation, scalable genomic interpretation, expanded panels, and clinically actionable hereditary screening solutions.

Drivers

• Comprehensive Integration of Expanded Genetic Testing Protocols in Carrier Screening
• Rising Consumer Demand for Direct-to-Consumer Genetic Testing Solutions
• Stringent Regulatory Frameworks and Ethical Guidelines Enhancing Test Reliability and Market Confidence
• Increasing Incorporation of Carrier Screening in Value-Based and Preventive Healthcare Models

Restraints

• Limited Reimbursement and High Cost of Carrier Screening Tests
• Complex Regulatory Environment and Privacy Concerns
• Limited Awareness and Insufficient Genetic Counseling Infrastructure

Opportunities

• Expansion of Direct-to-Consumer (DTC) Carrier Screening Services
• Integration of Carrier Screening with Broader Women's Health and Genomic Healthcare Solutions
• Adoption of Advanced Technologies to Enhance Accuracy and Reduce Turnaround Time

Challenges

• High Testing Costs and Reimbursement Limitations
• Data Privacy Concerns and Regulatory Compliance Complexity
• Limited Awareness and Lack of Genetic Counseling Infrastructure

Market Share Analysis

Carrier screening market represents a molecular diagnostic-driven competitive landscape driven by large clinical laboratory networks, and reproductive genetic testing companies. Quest Diagnostics, Labcorp, and Fulgent Genetic strengthen through wider laboratory infrastructure, flexible genetic testing platforms, molecular diagnostic capabilities, and reproductive health services. MedGenome, GeneDx, Tempus AI, Eurofins Scientific, and OPKO Health further contribute through genomic analytics, hereditary disease testing, regional laboratory networks, rare disease diagnostics, and expanded carrier screening capabilities.

Type Outlook

Based on Type, the market is segmented into Expanded and Targeted Disease. The Expanded market dominated the Global Carrier Screening Market by Type in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 2.5 billion by 2033, growing at a CAGR of 12 % during the forecast period. The Targeted Disease market is expected to witness a CAGR of 12.9% during (2026 - 2033).

Expanded leads the market as it enables simultaneous screening for a wide range of inherited genetic disorders through a single test. It is increasingly used in preconception and prenatal care due to its comprehensive reproductive risk assessment value. Targeted Disease remains important for family-history-based, ethnicity-based, and condition-specific screening where cost efficiency and clinical familiarity are important.

Technology Outlook

Based on Technology, the market is segmented into DNA Sequencing, Polymerase Chain Reaction, Microarrays, and Other Technology. The DNA Sequencing market dominated the Global Carrier Screening Market by Technology in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1.8 billion by 2033, growing at a CAGR of 11.7 % during the forecast period. The Polymerase Chain Reaction market is expected to witness a CAGR of 12.6% during (2026 - 2033). The Other Technology market is expected to witness a CAGR of 13% during (2026 - 2033).

DNA Sequencing leads due to high accuracy, broad mutation detection, and strong adoption of next-generation sequencing in carrier screening. Polymerase Chain Reaction supports rapid and cost-effective detection of known variants, while Microarrays enable high-throughput analysis of predefined mutations. Other Technology includes emerging molecular techniques that support specialized detection, workflow improvement, and complementary genomic testing.

End-use Outlook

Based on End-use, the market is segmented into Laboratories, Hospitals, Physician Offices & Clinics, and Other End-use. The Laboratories market dominated the Global Carrier Screening Market by End-use in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1.7 billion by 2033, growing at a CAGR of 11.7 % during the forecast period. The Hospitals market is expected to witness a CAGR of 12.5% during (2026 - 2033). Additionally, The Physician Offices & Clinics market is expected to witness highest CAGR of 13.2% during (2026 - 2033).

Laboratories lead the market due to advanced molecular diagnostic infrastructure, high testing capacity, bioinformatics expertise, and large sample volumes. Hospitals integrate carrier screening into prenatal diagnostics, reproductive medicine, and genetic counseling pathways. Physician Offices & Clinics expand access through routine reproductive health assessments, while Other End-use includes specialized diagnostic centers, fertility centers, and community healthcare facilities.

Medical Condition Outlook

Based on Medical Condition, the market is segmented into Cystic Fibrosis, Spinal Muscular Atrophy, Sickle Cell Disease, Tay-Sachs, Gaucher Disease, and Other Medical Condition. The Cystic Fibrosis market dominated the Global Carrier Screening Market by Medical Condition in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 1.2 billion by 2033, growing at a CAGR of 10.8 % during the forecast period. The Spinal Muscular Atrophy market is expected to witness a CAGR of 12% during (2026 - 2033). Additionally, The Sickle Cell Disease market is expected to witness highest CAGR of 13.3% during (2026 - 2033).

Cystic Fibrosis leads due to established screening guidelines, strong clinical awareness, and routine inclusion in reproductive genetic testing programs. Spinal Muscular Atrophy gains demand through early detection and expanded screening initiatives, while Sickle Cell Disease remains important among high-risk populations. Tay-Sachs and Gaucher Disease continue through targeted programs, while Other Medical Condition grows through expanded panels covering rare inherited disorders.

Regional Outlook

Region-wise, the Carrier Screening Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. North America held the largest share in carrier screening market by 2025 and is estimated to remain dominant with a market value of USD 1.6 billion, growing at a CAGR of 11.8% in the forecast period. The APAC market is predicted to grow at a CAGR of 13% during 2026-2033. Moreover, Europe market is predicted to expand with a CAGR of 11.9% in the forecast period.

North America region is witnessing market expansion because of advanced genetic testing adoption, mature healthcare infrastructure, favorable reimbursement support, and strong prenatal screening awareness. Europe market is shaped by precision medicine investments, genetic counseling services, and structured healthcare systems. Asia Pacific is gaining traction through healthcare investment, and molecular diagnostics expansion, while LAMEA is developing through enhancing reproductive healthcare access and growing awareness of genetic testing.

Recent Strategies Deployed in the Market

• 2026-June: Tempus announced its acquisition of Personalis in the United States to integrate minimal residual disease technology into its AI-enabled precision medicine platform and expand genomic sequencing capabilities.
• 2024-October: Tempus acquired Paige in the United States to strengthen digital pathology and AI capabilities, supporting integrated pathology imaging, genomic analytics, and future genetic testing workflows.
• Eurofins Scientific acquired PhAST in Germany to strengthen analytical testing capabilities, broaden its life sciences service portfolio, and support advanced genetic diagnostic services.
• Eurofins acquired ETM in Vietnam to expand regional laboratory operations and strengthen access to molecular diagnostic services across Southeast Asia.
• Tempus launched Tempus OS in the United States as a unified precision medicine platform integrating genomic, molecular, and clinical data for improved genetic information interpretation.
• Eurofins Viracor expanded its bioanalytical testing capabilities in the United States to increase laboratory capacity for complex genomic analyses and precision diagnostic services.
• 2024-February: Myriad Genetics expanded its precision medicine portfolio in the United States, strengthening hereditary disease testing and reproductive genetic services.
• MedGenome highlighted expanded carrier screening for maternal health in India, promoting comprehensive reproductive genetic testing for inherited disorder identification before pregnancy.
• 2024-June: Labcorp entered a strategic collaboration with Unilabs globally to expand access to specialty diagnostic and genetic testing services across Europe.
• 2023-November: Geneoscopy signed a multi-year agreement with Labcorp in the United States, strengthening Labcorp's molecular diagnostics infrastructure and broader genomic testing capabilities.

List of Key Companies Profiled

• Natera, Inc.
• Myriad Genetics, Inc.
• Labcorp Holdings Inc. (including select Invitae assets)
• Quest Diagnostics Incorporated
• Fulgent Genetics, Inc.
• Tempus AI, Inc. (Ambry Genetics)
• OPKO Health, Inc. (BioReference / GenPath)
• GeneDx Holdings Corp.
• Eurofins Scientific SE
• MedGenome Labs Ltd.

Global Carrier Screening Market Report Segmentation

By Type

• Expanded
• Targeted Disease

By Technology

• DNA Sequencing
• Polymerase Chain Reaction
• Microarrays
• Other Technology

By End-use

• Laboratories
• Hospitals
• Physician Offices & Clinics
• Other End-use

By Medical Condition

• Cystic Fibrosis
• Spinal Muscular Atrophy
• Sickle Cell Disease
• Tay-Sachs
• Gaucher Disease
• Other Medical Condition

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Research Scope & Methodology

• 1.1 Market Definition
• 1.2 Analysis Period & Currency
• 1.3 Segmentation
• 1.4 Carrier Screening Market, by Geography
• 1.5 Research Methodology

Chapter 2. Market Overview

• 2.1 COVID-19 Impact
• 2.2 Market Composition and Scenario

Chapter 3. Key Factors Impacting Market

• 3.1 Market Drivers
• 3.2 Market Restraints
• 3.3 Market Opportunities
• 3.4 Market Challenges
• 3.5 Market Trends
• 3.6 State of Competition
• 3.7 Market Consolidation
• 3.8 Key Customer Criteria

Chapter 4. Product Life Cycle

Chapter 5. Value Chain Analysis of Carrier Screening Market

Chapter 6. Competition Analysis - Global

• 6.1 Market Share Analysis
• 6.2 Recent Developments
  • 6.2.1 Mergers & Acquisitions
  • 6.2.2 Product Launch & Product Expansion
  • 6.2.3 Partnership, Collaboration & Agreements
  • 6.2.4 Geographical Expansion

Chapter 7. Segmentation By Type

• 7.1 Expanded
• 7.2 Targeted Disease

Chapter 8. Segmentation By Technology

• 8.1 DNA Sequencing
• 8.2 Polymerase Chain Reaction
• 8.3 Microarrays
• 8.4 Other Technology

Chapter 9. Segmentation By End-use

• 9.1 Laboratories
• 9.2 Hospitals
• 9.3 Physician Offices & Clinics
• 9.4 Other End-use

Chapter 10. Segmentation By Medical Condition

• 10.1 Cystic Fibrosis
• 10.2 Spinal Muscular Atrophy
• 10.3 Sickle Cell Disease
• 10.4 Tay-Sachs
• 10.5 Gaucher Disease
• 10.6 Other Medical Condition

Chapter 11. North America Market

• 11.1 Market Overview
• 11.2 Key Factors Impacting Market
  • 11.2.1 Market Drivers
  • 11.2.2 Market Restraints
  • 11.2.3 Market Opportunities
  • 11.2.4 Market Challenges
  • 11.2.5 Market Trends
  • 11.2.6 State of Competition
  • 11.2.7 Market Consolidation
  • 11.2.8 Key Customer Criteria
• 11.3 Product Life Cycle
• 11.4 Segmentation By Type
  • 11.4.1 Expanded
  • 11.4.2 Targeted Disease
• 11.5 Segmentation By Technology
  • 11.5.1 DNA Sequencing
  • 11.5.2 Polymerase Chain Reaction
  • 11.5.3 Microarrays
  • 11.5.4 Other Technology
• 11.6 Segmentation By End-use
  • 11.6.1 Laboratories
  • 11.6.2 Hospitals
  • 11.6.3 Physician Offices & Clinics
  • 11.6.4 Other End-use
• 11.7 Segmentation By Medical Condition
  • 11.7.1 Cystic Fibrosis
  • 11.7.2 Spinal Muscular Atrophy
  • 11.7.3 Sickle Cell Disease
  • 11.7.4 Tay-Sachs
  • 11.7.5 Gaucher Disease
  • 11.7.6 Other Medical Condition
• 11.8 Segmentation By Country
  • 11.8.1 US
    • 11.8.1.1 Segmentation By Type
      • 11.8.1.1.1 Expanded
      • 11.8.1.1.2 Targeted Disease
    • 11.8.1.2 Segmentation By Technology
      • 11.8.1.2.1 DNA Sequencing
      • 11.8.1.2.2 Polymerase Chain Reaction
      • 11.8.1.2.3 Microarrays
      • 11.8.1.2.4 Other Technology
    • 11.8.1.3 Segmentation By End-use
      • 11.8.1.3.1 Laboratories
      • 11.8.1.3.2 Hospitals
      • 11.8.1.3.3 Physician Offices & Clinics
      • 11.8.1.3.4 Other End-use
    • 11.8.1.4 Segmentation By Medical Condition
      • 11.8.1.4.1 Cystic Fibrosis
      • 11.8.1.4.2 Spinal Muscular Atrophy
      • 11.8.1.4.3 Sickle Cell Disease
      • 11.8.1.4.4 Gaucher Disease
      • 11.8.1.4.5 Tay-Sachs
      • 11.8.1.4.6 Other Medical Condition
  • 11.8.2 Canada
    • 11.8.2.1 Segmentation By Type
      • 11.8.2.1.1 Expanded
      • 11.8.2.1.2 Targeted Disease
    • 11.8.2.2 Segmentation By Technology
      • 11.8.2.2.1 DNA Sequencing
      • 11.8.2.2.2 Polymerase Chain Reaction
      • 11.8.2.2.3 Microarrays
      • 11.8.2.2.4 Other Technology
    • 11.8.2.3 Segmentation By End-use
      • 11.8.2.3.1 Laboratories
      • 11.8.2.3.2 Hospitals
      • 11.8.2.3.3 Physician Offices & Clinics
      • 11.8.2.3.4 Other End-use
    • 11.8.2.4 Segmentation By Medical Condition
      • 11.8.2.4.1 Cystic Fibrosis
      • 11.8.2.4.2 Spinal Muscular Atrophy
      • 11.8.2.4.3 Sickle Cell Disease
      • 11.8.2.4.4 Gaucher Disease
      • 11.8.2.4.5 Tay-Sachs
      • 11.8.2.4.6 Other Medical Condition
  • 11.8.3 Mexico
    • 11.8.3.1 Segmentation By Type
      • 11.8.3.1.1 Expanded
      • 11.8.3.1.2 Targeted Disease
    • 11.8.3.2 Segmentation By Technology
      • 11.8.3.2.1 DNA Sequencing
      • 11.8.3.2.2 Polymerase Chain Reaction
      • 11.8.3.2.3 Microarrays
      • 11.8.3.2.4 Other Technology
    • 11.8.3.3 Segmentation By End-use
      • 11.8.3.3.1 Laboratories
      • 11.8.3.3.2 Hospitals
      • 11.8.3.3.3 Physician Offices & Clinics
      • 11.8.3.3.4 Other End-use
    • 11.8.3.4 Segmentation By Medical Condition
      • 11.8.3.4.1 Cystic Fibrosis
      • 11.8.3.4.2 Spinal Muscular Atrophy
      • 11.8.3.4.3 Sickle Cell Disease
      • 11.8.3.4.4 Gaucher Disease
      • 11.8.3.4.5 Tay-Sachs
      • 11.8.3.4.6 Other Medical Condition
  • 11.8.4 Rest of North America
    • 11.8.4.1 Segmentation By Type
      • 11.8.4.1.1 Expanded
      • 11.8.4.1.2 Targeted Disease
    • 11.8.4.2 Segmentation By Technology
      • 11.8.4.2.1 DNA Sequencing
      • 11.8.4.2.2 Polymerase Chain Reaction
      • 11.8.4.2.3 Microarrays
      • 11.8.4.2.4 Other Technology
    • 11.8.4.3 Segmentation By End-use
      • 11.8.4.3.1 Laboratories
      • 11.8.4.3.2 Hospitals
      • 11.8.4.3.3 Physician Offices & Clinics
      • 11.8.4.3.4 Other End-use
    • 11.8.4.4 Segmentation By Medical Condition
      • 11.8.4.4.1 Cystic Fibrosis
      • 11.8.4.4.2 Spinal Muscular Atrophy
      • 11.8.4.4.3 Sickle Cell Disease
      • 11.8.4.4.4 Gaucher Disease
      • 11.8.4.4.5 Tay-Sachs
      • 11.8.4.4.6 Other Medical Condition

Chapter 12. Europe Market

• 12.1 Market Overview
• 12.2 Key Factors Impacting Market
  • 12.2.1 Market Drivers
  • 12.2.2 Market Restraints
  • 12.2.3 Market Opportunities
  • 12.2.4 Market Challenges
  • 12.2.5 Market Trends
  • 12.2.6 State of Competition
  • 12.2.7 Market Consolidation
  • 12.2.8 Key Customer Criteria
• 12.3 Product Life Cycle
• 12.4 Segmentation By Type
  • 12.4.1 Expanded
  • 12.4.2 Targeted Disease
• 12.5 Segmentation By Technology
  • 12.5.1 DNA Sequencing
  • 12.5.2 Polymerase Chain Reaction
  • 12.5.3 Microarrays
  • 12.5.4 Other Technology
• 12.6 Segmentation By End-use
  • 12.6.1 Laboratories
  • 12.6.2 Hospitals
  • 12.6.3 Physician Offices & Clinics
  • 12.6.4 Other End-use
• 12.7 Segmentation By Medical Condition
  • 12.7.1 Cystic Fibrosis
  • 12.7.2 Spinal Muscular Atrophy
  • 12.7.3 Sickle Cell Disease
  • 12.7.4 Tay-Sachs
  • 12.7.5 Gaucher Disease
  • 12.7.6 Other Medical Condition
• 12.8 Segmentation By Country
  • 12.8.1 Germany
    • 12.8.1.1 Segmentation By Type
      • 12.8.1.1.1 Expanded
      • 12.8.1.1.2 Targeted Disease
    • 12.8.1.2 Segmentation By Technology
      • 12.8.1.2.1 DNA Sequencing
      • 12.8.1.2.2 Polymerase Chain Reaction
      • 12.8.1.2.3 Microarrays
      • 12.8.1.2.4 Other Technology
    • 12.8.1.3 Segmentation By End-use
      • 12.8.1.3.1 Laboratories
      • 12.8.1.3.2 Hospitals
      • 12.8.1.3.3 Physician Offices & Clinics
      • 12.8.1.3.4 Other End-use
    • 12.8.1.4 Segmentation By Medical Condition
      • 12.8.1.4.1 Cystic Fibrosis
      • 12.8.1.4.2 Spinal Muscular Atrophy
      • 12.8.1.4.3 Sickle Cell Disease
      • 12.8.1.4.4 Gaucher Disease
      • 12.8.1.4.5 Tay-Sachs
      • 12.8.1.4.6 Other Medical Condition
  • 12.8.2 UK
    • 12.8.2.1 Segmentation By Type
      • 12.8.2.1.1 Expanded
      • 12.8.2.1.2 Targeted Disease
    • 12.8.2.2 Segmentation By Technology
      • 12.8.2.2.1 DNA Sequencing
      • 12.8.2.2.2 Polymerase Chain Reaction
      • 12.8.2.2.3 Microarrays
      • 12.8.2.2.4 Other Technology
    • 12.8.2.3 Segmentation By End-use
      • 12.8.2.3.1 Laboratories
      • 12.8.2.3.2 Hospitals
      • 12.8.2.3.3 Physician Offices & Clinics
      • 12.8.2.3.4 Other End-use
    • 12.8.2.4 Segmentation By Medical Condition
      • 12.8.2.4.1 Cystic Fibrosis
      • 12.8.2.4.2 Spinal Muscular Atrophy
      • 12.8.2.4.3 Sickle Cell Disease
      • 12.8.2.4.4 Gaucher Disease
      • 12.8.2.4.5 Tay-Sachs
      • 12.8.2.4.6 Other Medical Condition
  • 12.8.3 France
    • 12.8.3.1 Segmentation By Type
      • 12.8.3.1.1 Expanded
      • 12.8.3.1.2 Targeted Disease
    • 12.8.3.2 Segmentation By Technology
      • 12.8.3.2.1 DNA Sequencing
      • 12.8.3.2.2 Polymerase Chain Reaction
      • 12.8.3.2.3 Microarrays
      • 12.8.3.2.4 Other Technology
    • 12.8.3.3 Segmentation By End-use
      • 12.8.3.3.1 Laboratories
      • 12.8.3.3.2 Hospitals
      • 12.8.3.3.3 Physician Offices & Clinics
      • 12.8.3.3.4 Other End-use
    • 12.8.3.4 Segmentation By Medical Condition
      • 12.8.3.4.1 Cystic Fibrosis
      • 12.8.3.4.2 Spinal Muscular Atrophy
      • 12.8.3.4.3 Sickle Cell Disease
      • 12.8.3.4.4 Gaucher Disease
      • 12.8.3.4.5 Tay-Sachs
      • 12.8.3.4.6 Other Medical Condition
  • 12.8.4 Russia
    • 12.8.4.1 Segmentation By Type
      • 12.8.4.1.1 Expanded
      • 12.8.4.1.2 Targeted Disease
    • 12.8.4.2 Segmentation By Technology
      • 12.8.4.2.1 DNA Sequencing
      • 12.8.4.2.2 Polymerase Chain Reaction
      • 12.8.4.2.3 Microarrays
      • 12.8.4.2.4 Other Technology
    • 12.8.4.3 Segmentation By End-use
      • 12.8.4.3.1 Laboratories
      • 12.8.4.3.2 Hospitals
      • 12.8.4.3.3 Physician Offices & Clinics
      • 12.8.4.3.4 Other End-use
    • 12.8.4.4 Segmentation By Medical Condition
      • 12.8.4.4.1 Cystic Fibrosis
      • 12.8.4.4.2 Spinal Muscular Atrophy
      • 12.8.4.4.3 Sickle Cell Disease
      • 12.8.4.4.4 Gaucher Disease
      • 12.8.4.4.5 Tay-Sachs
      • 12.8.4.4.6 Other Medical Condition
  • 12.8.5 Spain
    • 12.8.5.1 Segmentation By Type
      • 12.8.5.1.1 Expanded
      • 12.8.5.1.2 Targeted Disease
    • 12.8.5.2 Segmentation By Technology
      • 12.8.5.2.1 DNA Sequencing
      • 12.8.5.2.2 Polymerase Chain Reaction
      • 12.8.5.2.3 Microarrays
      • 12.8.5.2.4 Other Technology
    • 12.8.5.3 Segmentation By End-use
      • 12.8.5.3.1 Laboratories
      • 12.8.5.3.2 Hospitals
      • 12.8.5.3.3 Physician Offices & Clinics
      • 12.8.5.3.4 Other End-use
    • 12.8.5.4 Segmentation By Medical Condition
      • 12.8.5.4.1 Cystic Fibrosis
      • 12.8.5.4.2 Spinal Muscular Atrophy
      • 12.8.5.4.3 Sickle Cell Disease
      • 12.8.5.4.4 Gaucher Disease
      • 12.8.5.4.5 Tay-Sachs
      • 12.8.5.4.6 Other Medical Condition
  • 12.8.6 Italy
    • 12.8.6.1 Segmentation By Type
      • 12.8.6.1.1 Expanded
      • 12.8.6.1.2 Targeted Disease
    • 12.8.6.2 Segmentation By Technology
      • 12.8.6.2.1 DNA Sequencing
      • 12.8.6.2.2 Polymerase Chain Reaction
      • 12.8.6.2.3 Microarrays
      • 12.8.6.2.4 Other Technology
    • 12.8.6.3 Segmentation By End-use
      • 12.8.6.3.1 Laboratories
      • 12.8.6.3.2 Hospitals
      • 12.8.6.3.3 Physician Offices & Clinics
      • 12.8.6.3.4 Other End-use
    • 12.8.6.4 Segmentation By Medical Condition
      • 12.8.6.4.1 Cystic Fibrosis
      • 12.8.6.4.2 Spinal Muscular Atrophy
      • 12.8.6.4.3 Sickle Cell Disease
      • 12.8.6.4.4 Gaucher Disease
      • 12.8.6.4.5 Tay-Sachs
      • 12.8.6.4.6 Other Medical Condition
  • 12.8.7 Rest of Europe
    • 12.8.7.1 Segmentation By Type
      • 12.8.7.1.1 Expanded
      • 12.8.7.1.2 Targeted Disease
    • 12.8.7.2 Segmentation By Technology
      • 12.8.7.2.1 DNA Sequencing
      • 12.8.7.2.2 Polymerase Chain Reaction
      • 12.8.7.2.3 Microarrays
      • 12.8.7.2.4 Other Technology
    • 12.8.7.3 Segmentation By End-use
      • 12.8.7.3.1 Laboratories
      • 12.8.7.3.2 Hospitals
      • 12.8.7.3.3 Physician Offices & Clinics
      • 12.8.7.3.4 Other End-use
    • 12.8.7.4 Segmentation By Medical Condition
      • 12.8.7.4.1 Cystic Fibrosis
      • 12.8.7.4.2 Spinal Muscular Atrophy
      • 12.8.7.4.3 Sickle Cell Disease
      • 12.8.7.4.4 Gaucher Disease
      • 12.8.7.4.5 Tay-Sachs
      • 12.8.7.4.6 Other Medical Condition

Chapter 13. Asia Pacific Market

• 13.1 Market Overview
• 13.2 Key Factors Impacting Market
  • 13.2.1 Market Drivers
  • 13.2.2 Market Restraints
  • 13.2.3 Market Opportunities
  • 13.2.4 Market Challenges
  • 13.2.5 Market Trends
  • 13.2.6 State of Competition
  • 13.2.7 Market Consolidation
  • 13.2.8 Key Customer Criteria
• 13.3 Product Life Cycle
• 13.4 Segmentation By Type
  • 13.4.1 Expanded
  • 13.4.2 Targeted Disease
• 13.5 Segmentation By Technology
  • 13.5.1 DNA Sequencing
  • 13.5.2 Polymerase Chain Reaction
  • 13.5.3 Microarrays
  • 13.5.4 Other Technology
• 13.6 Segmentation By End-use
  • 13.6.1 Laboratories
  • 13.6.2 Hospitals
  • 13.6.3 Physician Offices & Clinics
  • 13.6.4 Other End-use
• 13.7 Segmentation By Medical Condition
  • 13.7.1 Cystic Fibrosis
  • 13.7.2 Spinal Muscular Atrophy
  • 13.7.3 Sickle Cell Disease
  • 13.7.4 Tay-Sachs
  • 13.7.5 Gaucher Disease
• 13.8 Segmentation By Country
  • 13.8.1 China
    • 13.8.1.1 Segmentation By Type
      • 13.8.1.1.1 Expanded
      • 13.8.1.1.2 Targeted Disease
    • 13.8.1.2 Segmentation By Technology
      • 13.8.1.2.1 DNA Sequencing
      • 13.8.1.2.2 Polymerase Chain Reaction
      • 13.8.1.2.3 Microarrays
      • 13.8.1.2.4 Other Technology
    • 13.8.1.3 Segmentation By End-use
      • 13.8.1.3.1 Laboratories
      • 13.8.1.3.2 Hospitals
      • 13.8.1.3.3 Physician Offices & Clinics
      • 13.8.1.3.4 Other End-use
    • 13.8.1.4 Segmentation By Medical Condition
      • 13.8.1.4.1 Cystic Fibrosis
      • 13.8.1.4.2 Spinal Muscular Atrophy
      • 13.8.1.4.3 Sickle Cell Disease
      • 13.8.1.4.4 Gaucher Disease
      • 13.8.1.4.5 Tay-Sachs
      • 13.8.1.4.6 Other Medical Condition
  • 13.8.2 Japan
    • 13.8.2.1 Segmentation By Type
      • 13.8.2.1.1 Expanded
      • 13.8.2.1.2 Targeted Disease
    • 13.8.2.2 Segmentation By Technology
      • 13.8.2.2.1 DNA Sequencing
      • 13.8.2.2.2 Polymerase Chain Reaction
      • 13.8.2.2.3 Microarrays
      • 13.8.2.2.4 Other Technology
    • 13.8.2.3 Segmentation By End-use
      • 13.8.2.3.1 Laboratories
      • 13.8.2.3.2 Hospitals
      • 13.8.2.3.3 Physician Offices & Clinics
      • 13.8.2.3.4 Other End-use
    • 13.8.2.4 Segmentation By Medical Condition
      • 13.8.2.4.1 Cystic Fibrosis
      • 13.8.2.4.2 Spinal Muscular Atrophy
      • 13.8.2.4.3 Sickle Cell Disease
      • 13.8.2.4.4 Gaucher Disease
      • 13.8.2.4.5 Tay-Sachs
      • 13.8.2.4.6 Other Medical Condition
  • 13.8.3 India
    • 13.8.3.1 Segmentation By Type
      • 13.8.3.1.1 Expanded
      • 13.8.3.1.2 Targeted Disease
    • 13.8.3.2 Segmentation By Technology
      • 13.8.3.2.1 DNA Sequencing
      • 13.8.3.2.2 Polymerase Chain Reaction
      • 13.8.3.2.3 Microarrays
      • 13.8.3.2.4 Other Technology
    • 13.8.3.3 Segmentation By End-use
      • 13.8.3.3.1 Laboratories
      • 13.8.3.3.2 Hospitals
      • 13.8.3.3.3 Physician Offices & Clinics
      • 13.8.3.3.4 Other End-use
    • 13.8.3.4 Segmentation By Medical Condition
      • 13.8.3.4.1 Cystic Fibrosis
      • 13.8.3.4.2 Spinal Muscular Atrophy
      • 13.8.3.4.3 Sickle Cell Disease
      • 13.8.3.4.4 Gaucher Disease
      • 13.8.3.4.5 Tay-Sachs
      • 13.8.3.4.6 Other Medical Condition
  • 13.8.4 South Korea
    • 13.8.4.1 Segmentation By Type
      • 13.8.4.1.1 Expanded
      • 13.8.4.1.2 Targeted Disease
    • 13.8.4.2 Segmentation By Technology
      • 13.8.4.2.1 DNA Sequencing
      • 13.8.4.2.2 Polymerase Chain Reaction
      • 13.8.4.2.3 Microarrays
      • 13.8.4.2.4 Other Technology
    • 13.8.4.3 Segmentation By End-use
      • 13.8.4.3.1 Laboratories
      • 13.8.4.3.2 Hospitals
      • 13.8.4.3.3 Physician Offices & Clinics
      • 13.8.4.3.4 Other End-use
    • 13.8.4.4 Segmentation By Medical Condition
      • 13.8.4.4.1 Cystic Fibrosis
      • 13.8.4.4.2 Spinal Muscular Atrophy
      • 13.8.4.4.3 Sickle Cell Disease
      • 13.8.4.4.4 Gaucher Disease
      • 13.8.4.4.5 Tay-Sachs
      • 13.8.4.4.6 Other Medical Condition
  • 13.8.5 Singapore
    • 13.8.5.1 Segmentation By Type
      • 13.8.5.1.1 Expanded
      • 13.8.5.1.2 Targeted Disease
    • 13.8.5.2 Segmentation By Technology
      • 13.8.5.2.1 DNA Sequencing
      • 13.8.5.2.2 Polymerase Chain Reaction
      • 13.8.5.2.3 Microarrays
      • 13.8.5.2.4 Other Technology
    • 13.8.5.3 Segmentation By End-use
      • 13.8.5.3.1 Laboratories
      • 13.8.5.3.2 Hospitals
      • 13.8.5.3.3 Physician Offices & Clinics
      • 13.8.5.3.4 Other End-use
    • 13.8.5.4 Segmentation By Medical Condition
      • 13.8.5.4.1 Cystic Fibrosis
      • 13.8.5.4.2 Spinal Muscular Atrophy
      • 13.8.5.4.3 Sickle Cell Disease
      • 13.8.5.4.4 Gaucher Disease
      • 13.8.5.4.5 Tay-Sachs
      • 13.8.5.4.6 Other Medical Condition
  • 13.8.6 Malaysia
    • 13.8.6.1 Segmentation By Type
      • 13.8.6.1.1 Expanded
      • 13.8.6.1.2 Targeted Disease
    • 13.8.6.2 Segmentation By Technology
      • 13.8.6.2.1 DNA Sequencing
      • 13.8.6.2.2 Polymerase Chain Reaction
      • 13.8.6.2.3 Microarrays
      • 13.8.6.2.4 Other Technology
    • 13.8.6.3 Segmentation By End-use
      • 13.8.6.3.1 Laboratories
      • 13.8.6.3.2 Hospitals
      • 13.8.6.3.3 Physician Offices & Clinics
      • 13.8.6.3.4 Other End-use
    • 13.8.6.4 Segmentation By Medical Condition
      • 13.8.6.4.1 Cystic Fibrosis
      • 13.8.6.4.2 Spinal Muscular Atrophy
      • 13.8.6.4.3 Sickle Cell Disease
      • 13.8.6.4.4 Gaucher Disease
      • 13.8.6.4.5 Tay-Sachs
      • 13.8.6.4.6 Other Medical Condition
  • 13.8.7 Rest of Asia Pacific
    • 13.8.7.1 Segmentation By Type
      • 13.8.7.1.1 Expanded
      • 13.8.7.1.2 Targeted Disease
    • 13.8.7.2 Segmentation By Technology
      • 13.8.7.2.1 DNA Sequencing
      • 13.8.7.2.2 Polymerase Chain Reaction
      • 13.8.7.2.3 Microarrays
      • 13.8.7.2.4 Other Technology
    • 13.8.7.3 Segmentation By End-use
      • 13.8.7.3.1 Laboratories
      • 13.8.7.3.2 Hospitals
      • 13.8.7.3.3 Physician Offices & Clinics
      • 13.8.7.3.4 Other End-use
    • 13.8.7.4 Segmentation By Medical Condition
      • 13.8.7.4.1 Cystic Fibrosis
      • 13.8.7.4.2 Spinal Muscular Atrophy
      • 13.8.7.4.3 Sickle Cell Disease
      • 13.8.7.4.4 Gaucher Disease
      • 13.8.7.4.5 Tay-Sachs
      • 13.8.7.4.6 Other Medical Condition

Chapter 14. LAMEA Market

• 14.1 Market Overview
• 14.2 Key Factors Impacting Market
  • 14.2.1 Market Drivers
  • 14.2.2 Market Restraints
  • 14.2.3 Market Opportunities
  • 14.2.4 Market Challenges
  • 14.2.5 Market Trends
  • 14.2.6 State of Competition
  • 14.2.7 Market Consolidation
  • 14.2.8 Key Customer Criteria
• 14.3 Product Life Cycle
• 14.4 Segmentation By Type
  • 14.4.1 Expanded
  • 14.4.2 Targeted Disease
• 14.5 Segmentation By Technology
  • 14.5.1 DNA Sequencing
  • 14.5.2 Polymerase Chain Reaction
  • 14.5.3 Microarrays
  • 14.5.4 Other Technology
• 14.6 Segmentation By End-use
  • 14.6.1 Laboratories
  • 14.6.2 Hospitals
  • 14.6.3 Physician Offices & Clinics
  • 14.6.4 Other End-use
• 14.7 Segmentation By Medical Condition
  • 14.7.1 Cystic Fibrosis
  • 14.7.2 Spinal Muscular Atrophy
  • 14.7.3 Sickle Cell Disease
  • 14.7.4 Gaucher Disease
  • 14.7.5 Tay-Sachs
  • 14.7.6 Other Medical Condition
• 14.8 Segmentation By Country
  • 14.8.1 Brazil
    • 14.8.1.1 Segmentation By Type
      • 14.8.1.1.1 Expanded
      • 14.8.1.1.2 Targeted Disease
    • 14.8.1.2 Segmentation By Technology
      • 14.8.1.2.1 DNA Sequencing
      • 14.8.1.2.2 Polymerase Chain Reaction
      • 14.8.1.2.3 Microarrays
      • 14.8.1.2.4 Other Technology
    • 14.8.1.3 Segmentation By End-use
      • 14.8.1.3.1 Laboratories
      • 14.8.1.3.2 Hospitals
      • 14.8.1.3.3 Physician Offices & Clinics
      • 14.8.1.3.4 Other End-use
    • 14.8.1.4 Segmentation By Medical Condition
      • 14.8.1.4.1 Cystic Fibrosis
      • 14.8.1.4.2 Spinal Muscular Atrophy
      • 14.8.1.4.3 Sickle Cell Disease
      • 14.8.1.4.4 Gaucher Disease
      • 14.8.1.4.5 Tay-Sachs
      • 14.8.1.4.6 Other Medical Condition
  • 14.8.2 Argentina
    • 14.8.2.1 Segmentation By Type
      • 14.8.2.1.1 Expanded
      • 14.8.2.1.2 Targeted Disease
    • 14.8.2.2 Segmentation By Technology
      • 14.8.2.2.1 DNA Sequencing
      • 14.8.2.2.2 Polymerase Chain Reaction
      • 14.8.2.2.3 Microarrays
      • 14.8.2.2.4 Other Technology
    • 14.8.2.3 Segmentation By End-use
      • 14.8.2.3.1 Laboratories
      • 14.8.2.3.2 Hospitals
      • 14.8.2.3.3 Physician Offices & Clinics
      • 14.8.2.3.4 Other End-use
    • 14.8.2.4 Segmentation By Medical Condition
      • 14.8.2.4.1 Cystic Fibrosis
      • 14.8.2.4.2 Spinal Muscular Atrophy
      • 14.8.2.4.3 Sickle Cell Disease
      • 14.8.2.4.4 Gaucher Disease
      • 14.8.2.4.5 Tay-Sachs
      • 14.8.2.4.6 Other Medical Condition
  • 14.8.3 UAE
    • 14.8.3.1 Segmentation By Type
      • 14.8.3.1.1 Expanded
      • 14.8.3.1.2 Targeted Disease
    • 14.8.3.2 Segmentation By Technology
      • 14.8.3.2.1 DNA Sequencing
      • 14.8.3.2.2 Polymerase Chain Reaction
      • 14.8.3.2.3 Microarrays
      • 14.8.3.2.4 Other Technology
    • 14.8.3.3 Segmentation By End-use
      • 14.8.3.3.1 Laboratories
      • 14.8.3.3.2 Hospitals
      • 14.8.3.3.3 Physician Offices & Clinics
      • 14.8.3.3.4 Other End-use
    • 14.8.3.4 Segmentation By Medical Condition
      • 14.8.3.4.1 Cystic Fibrosis
      • 14.8.3.4.2 Spinal Muscular Atrophy
      • 14.8.3.4.3 Sickle Cell Disease
      • 14.8.3.4.4 Gaucher Disease
      • 14.8.3.4.5 Tay-Sachs
      • 14.8.3.4.6 Other Medical Condition
  • 14.8.4 Saudi Arabia
    • 14.8.4.1 Segmentation By Type
      • 14.8.4.1.1 Expanded
      • 14.8.4.1.2 Targeted Disease
    • 14.8.4.2 Segmentation By Technology
      • 14.8.4.2.1 DNA Sequencing
      • 14.8.4.2.2 Polymerase Chain Reaction
      • 14.8.4.2.3 Microarrays
      • 14.8.4.2.4 Other Technology
    • 14.8.4.3 Segmentation By End-use
      • 14.8.4.3.1 Laboratories
      • 14.8.4.3.2 Hospitals
      • 14.8.4.3.3 Physician Offices & Clinics
      • 14.8.4.3.4 Other End-use
    • 14.8.4.4 Segmentation By Medical Condition
      • 14.8.4.4.1 Cystic Fibrosis
      • 14.8.4.4.2 Spinal Muscular Atrophy
      • 14.8.4.4.3 Sickle Cell Disease
      • 14.8.4.4.4 Gaucher Disease
      • 14.8.4.4.5 Tay-Sachs
      • 14.8.4.4.6 Other Medical Condition
  • 14.8.5 South Africa
    • 14.8.5.1 Segmentation By Type
      • 14.8.5.1.1 Expanded
      • 14.8.5.1.2 Targeted Disease
    • 14.8.5.2 Segmentation By Technology
      • 14.8.5.2.1 DNA Sequencing
      • 14.8.5.2.2 Polymerase Chain Reaction
      • 14.8.5.2.3 Microarrays
      • 14.8.5.2.4 Other Technology
    • 14.8.5.3 Segmentation By End-use
      • 14.8.5.3.1 Laboratories
      • 14.8.5.3.2 Hospitals
      • 14.8.5.3.3 Physician Offices & Clinics
      • 14.8.5.3.4 Other End-use
    • 14.8.5.4 Segmentation By Medical Condition
      • 14.8.5.4.1 Cystic Fibrosis
      • 14.8.5.4.2 Spinal Muscular Atrophy
      • 14.8.5.4.3 Sickle Cell Disease
      • 14.8.5.4.4 Gaucher Disease
      • 14.8.5.4.5 Tay-Sachs
      • 14.8.5.4.6 Other Medical Condition
  • 14.8.6 Nigeria
    • 14.8.6.1 Segmentation By Type
      • 14.8.6.1.1 Expanded
      • 14.8.6.1.2 Targeted Disease
    • 14.8.6.2 Segmentation By Technology
      • 14.8.6.2.1 DNA Sequencing
      • 14.8.6.2.2 Polymerase Chain Reaction
      • 14.8.6.2.3 Microarrays
      • 14.8.6.2.4 Other Technology
    • 14.8.6.3 Segmentation By End-use
      • 14.8.6.3.1 Laboratories
      • 14.8.6.3.2 Hospitals
      • 14.8.6.3.3 Physician Offices & Clinics
      • 14.8.6.3.4 Other End-use
    • 14.8.6.4 Segmentation By Medical Condition
      • 14.8.6.4.1 Cystic Fibrosis
      • 14.8.6.4.2 Spinal Muscular Atrophy
      • 14.8.6.4.3 Sickle Cell Disease
      • 14.8.6.4.4 Gaucher Disease
      • 14.8.6.4.5 Tay-Sachs
      • 14.8.6.4.6 Other Medical Condition
  • 14.8.7 Rest of LAMEA
    • 14.8.7.1 Segmentation By Type
      • 14.8.7.1.1 Expanded
      • 14.8.7.1.2 Targeted Disease
    • 14.8.7.2 Segmentation By Technology
      • 14.8.7.2.1 DNA Sequencing
      • 14.8.7.2.2 Polymerase Chain Reaction
      • 14.8.7.2.3 Microarrays
      • 14.8.7.2.4 Other Technology
    • 14.8.7.3 Segmentation By End-use
      • 14.8.7.3.1 Laboratories
      • 14.8.7.3.2 Hospitals
      • 14.8.7.3.3 Physician Offices & Clinics
      • 14.8.7.3.4 Other End-use
    • 14.8.7.4 Segmentation By Medical Condition
      • 14.8.7.4.1 Cystic Fibrosis
      • 14.8.7.4.2 Spinal Muscular Atrophy
      • 14.8.7.4.3 Sickle Cell Disease
      • 14.8.7.4.4 Gaucher Disease
      • 14.8.7.4.5 Tay-Sachs
      • 14.8.7.4.6 Other Medical Condition

Chapter 15. Company Snapshots

• 15.1 Natera, Inc.
  • 15.1.1 Business Overview
  • 15.1.2 Key Information
  • 15.1.3 Company Focus on Carrier Screening Market
  • 15.1.4 Strategic Insights
  • 15.1.5 Strategy Deployed
  • 15.1.6 Product & Service Portfolio
  • 15.1.7 Representative Products
  • 15.1.8 Capability Overview
  • 15.1.9 Technology & Innovation Focus
  • 15.1.10 SWOT Analysis
  • 15.1.11 Customers / End Users
  • 15.1.12 Competitive Positioning
  • 15.1.13 Key Differentiators
  • 15.1.14 Portfolio Matrix
  • 15.1.15 Analyst View
  • 15.1.16 Future Outlook
• 15.2 Myriad Genetics, Inc.
  • 15.2.1 Business Overview
  • 15.2.2 Key Information
  • 15.2.3 Company Focus on Carrier Screening Market
  • 15.2.4 Strategic Insights
  • 15.2.5 Strategy Deployed
  • 15.2.6 Product & Service Portfolio
  • 15.2.7 Representative Products
  • 15.2.8 Capability Overview
  • 15.2.9 Technology & Innovation Focus
  • 15.2.10 SWOT Analysis
  • 15.2.11 Customers / End Users
  • 15.2.12 Competitive Positioning
  • 15.2.13 Key Differentiators
  • 15.2.14 Portfolio Matrix
  • 15.2.15 Analyst View
  • 15.2.16 Future Outlook
• 15.3 Labcorp Holdings Inc.
  • 15.3.1 Business Overview
  • 15.3.2 Key Information
  • 15.3.3 Company Focus on Carrier Screening Market
  • 15.3.4 Strategic Insights
  • 15.3.5 Strategy Deployed
  • 15.3.6 Product & Service Portfolio
  • 15.3.7 Representative Products / Services
  • 15.3.8 Capability Overview
  • 15.3.9 Technology & Innovation Focus
  • 15.3.10 SWOT Analysis
  • 15.3.11 Customers / End Users
  • 15.3.12 Competitive Positioning
  • 15.3.13 Key Differentiators
  • 15.3.14 Portfolio Matrix
  • 15.3.15 Analyst View
  • 15.3.16 Future Outlook
• 15.4 Quest Diagnostics Incorporated
  • 15.4.1 Business Overview
  • 15.4.2 Key Information
  • 15.4.3 Company Focus on Carrier Screening Market
  • 15.4.4 Strategic Insights on Carrier Screening Market
  • 15.4.5 Strategy Deployed for Carrier Screening Market
  • 15.4.6 Product & Service Portfolio
  • 15.4.7 Representative Products / Services
  • 15.4.8 Capability Overview
  • 15.4.9 Technology & Innovation Focus
  • 15.4.10 SWOT Analysis
  • 15.4.11 Customers / End Users
  • 15.4.12 Competitive Positioning
  • 15.4.13 Key Differentiators
  • 15.4.14 Portfolio Matrix
  • 15.4.15 Analyst View
  • 15.4.16 Future Outlook
• 15.5 Fulgent Genetics, Inc.
  • 15.5.1 Business Overview
  • 15.5.2 Key Information
  • 15.5.3 Company Focus on Carrier Screening Market
  • 15.5.4 Strategic Insights
  • 15.5.5 Strategy Deployed
  • 15.5.6 Product & Service Portfolio
  • 15.5.7 Representative Products / Services
  • 15.5.8 Capability Overview
  • 15.5.9 Technology & Innovation Focus
  • 15.5.10 SWOT Analysis
  • 15.5.11 Customers / End Users
  • 15.5.12 Competitive Positioning
  • 15.5.13 Key Differentiators
  • 15.5.14 Portfolio Matrix
  • 15.5.15 Analyst View
  • 15.5.16 Future Outlook
• 15.6 Tempus AI, Inc.
  • 15.6.1 Business Overview
  • 15.6.2 Key Information
  • 15.6.3 Company Focus on Carrier Screening Market
  • 15.6.4 Strategic Insights
  • 15.6.5 Strategy Deployed for Carrier Screening Market
  • 15.6.6 Product & Service Portfolio
  • 15.6.7 Representative Products / Services
  • 15.6.8 Capability Overview
  • 15.6.9 Technology & Innovation Focus
  • 15.6.10 SWOT Analysis
  • 15.6.11 Customers / End Users
  • 15.6.12 Competitive Positioning
  • 15.6.13 Key Differentiators
  • 15.6.14 Portfolio Matrix
  • 15.6.15 Analyst View
  • 15.6.16 Future Outlook
• 15.7 OPKO Health, Inc.
  • 15.7.1 Business Overview
  • 15.7.2 Company Profile
  • 15.7.3 Company Focus on Carrier Screening Market
  • 15.7.4 Strategic Insights on Carrier Screening Market
  • 15.7.5 Strategy Deployed for Carrier Screening Market
  • 15.7.6 Product & Service Portfolio
  • 15.7.7 Representative Products / Services
  • 15.7.8 Capability Overview
  • 15.7.9 Technology & Innovation Focus
  • 15.7.10 SWOT Analysis
  • 15.7.11 Customers / End Users
  • 15.7.12 Competitive Positioning
  • 15.7.13 Key Differentiators
  • 15.7.14 Portfolio Matrix
  • 15.7.15 Analyst View
  • 15.7.16 Future Outlook
• 15.8 GeneDx Holdings Corp.
  • 15.8.1 Business Overview
  • 15.8.2 Key Information
  • 15.8.3 Company Focus on Carrier Screening Market
  • 15.8.4 Strategic Insights
  • 15.8.5 Strategy Deployed
  • 15.8.6 Product & Service Portfolio
  • 15.8.7 Representative Products / Services
  • 15.8.8 Capability Overview
  • 15.8.9 Technology & Innovation Focus
  • 15.8.10 SWOT Analysis
  • 15.8.11 Customers / End Users
  • 15.8.12 Competitive Positioning
  • 15.8.13 Key Differentiators
  • 15.8.14 Portfolio Matrix
  • 15.8.15 Analyst View
  • 15.8.16 Future Outlook
• 15.9 Eurofins Scientific SE
  • 15.9.1 Business Overview
  • 15.9.2 Key Information
  • 15.9.3 Company Focus on Carrier Screening Market
  • 15.9.4 Strategic Insights on Carrier Screening Market
  • 15.9.5 Strategy Deployed for Carrier Screening Market
  • 15.9.6 Product & Service Portfolio
  • 15.9.7 Representative Products / Services
  • 15.9.8 Capability Overview
  • 15.9.9 Technology & Innovation Focus
  • 15.9.10 SWOT Analysis
  • 15.9.11 Customers / End Users
  • 15.9.12 Competitive Positioning
  • 15.9.13 Key Differentiators
  • 15.9.14 Portfolio Matrix
  • 15.9.15 Analyst View
  • 15.9.16 Future Outlook
• 15.10 MedGenome Labs Ltd.
  • 15.10.1 Business Overview
  • 15.10.2 Key Information
  • 15.10.3 Company Focus on Carrier Screening Market
  • 15.10.4 Strategic Insights
  • 15.10.5 Strategy Deployed
  • 15.10.6 Product & Service Portfolio
  • 15.10.7 Representative Products / Services
  • 15.10.8 Capability Overview
  • 15.10.9 Technology & Innovation Focus
  • 15.10.10 SWOT Analysis
  • 15.10.11 Customers / End Users
  • 15.10.12 Competitive Positioning
  • 15.10.13 Key Differentiators
  • 15.10.14 Portfolio Matrix
  • 15.10.15 Analyst View
  • 15.10.16 Future Outlook

Chapter 16. Winning Imperatives of Carrier Screening Market